Functional and Pharmacokinetic Properties of Antibody-Avidin Fusion Proteins

Journal of Immunology

Volumn 158, Issue 10, 1997, Pages 4797-4804

  Shin, Seung Uon ^a,b   Wu, Dafang ^c   Ramanathan, Rajeev ^d   Pardridge, William M ^c   Morrison, Sherie L ^b  

^a Hallym University   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; HYBRID PROTEIN; IMMUNOGLOBULIN G;

ANIMAL; ANTIBODY COMBINING SITE; ARTICLE; CHEMISTRY; CHICKEN; HUMAN; MALE; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; RAT; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; AVIDIN; BASE SEQUENCE; BINDING SITES, ANTIBODY; BIOTIN; CHICKENS; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031570025     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kohler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495.
2. Zuckier, L. S., L. Georgescu, C. J. Chang, M. D. Scharff, and S. L. Morrison. 1994. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 73(Suppl. 3):794.
3. Schier, R., J. Bye, G. Apell, A. McCall, G. P. Adams, M. Malmqvist, L. M. Weiner, and J. D. Marks. 1996. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J. Mol. Biol. 255:28.
4. L regions contribute to the antigenicity of anti-idiotypic antibody that mimics melanoma associated ganglioside GM3. Cell Biophys. 24-25:65.
5. Tao, M. H., and S. L. Morrison. 1989. Studies of aglycosylated chimeric mouse-human IgG: role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143:2595.
6. Tao, M. H., R. I. Smith, and S. L. Morrison. 1993. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 178:661.
7. Smith, R. I., and S. L. Morrison. 1994. Recombinant polymeric IgG: an approach to engineering more potent antibodies. Nature Biotechnol. 12:683.
8. Smith, R. I., M. J. Coloma, and S. L. Morrison. 1995. Addition of a μ-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J. Immunol. 154:2226.
9. Goldenberg, D. M. 1993. Monoclonal antibodies in cancer detection and therapy. Am. J. Med. 94:297.
10. Shin, S.-U., and S. L. Morrison. 1990. Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential application for cellular targeting. Proc. Natl. Acad. Sci. USA 87:5322.
11. Shin, S.-U., P. Friden, M. Moran, and S. L. Morrison. 1994. Functional properties of antibody insulin-like growth factor fusion proteins. J. Biol. Chem. 269:4979.
12. Shin, S.-U., P. Friden, M. Moran, T. Olson, Y.-S. Kang, W. M. Pardridge, and S. L. Morrison. 1995. Transferrin-antibody fusion proteins are effective in brain targeting. Proc. Natl. Acad. Sci. USA 92:2820.
13. Capon, D. J., S. M. Chamow, J. Mordenti, S. A. Marsters, T. Gregory, H. Mitsuya, R. A. Byrn, C. Lucas, F. M. Wurm, J. E. Groopman, S. Broder, and D. H. Smith. 1989. Designing CD4 immunoadhesins for AIDS therapy. Nature 337:525.
14. Martin, S., J. M. Casasnovas, D. E. Staunton, and T, A. Springer. 1993. Efficient neutralization and disruption of rhinovirus by chimeric ICAM-1/immunoglobulin molecules. J. Virol. 67:3561.
15. Haak-Frendscho, M., S. A. Marsters, J. Mordenti, S. Brady, N. A. Gillett, S. A. Chen, and A. Ashkenazi. 1994. Inhibition of TNF by a TNF receptor immunoadhesin: comparison to an anti-TNF monoclonal antibody. J. Immunol. 152:1347.
16. Green, N. M. 1975. Avidin. Adv. Protein Chem. 29:85.
17. Green, N. M. 1990. Avidin and streptavidin. Methods Enzymol. 184:51.
18. Yoshikawa, T., and W. M. Pardridge. 1992. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J. Pharmacol. Exp. Ther. 263:897.
19. Pardridge, W. M., R. J. Boado, and J. L. Buciak. 1993. Drug delivery of antisense oligonucleotides or peptides to tissues in vivo using an avidin-biotin system. Drug Delivery 1:43.
20. Gope, M. L., R. A. Keinanen, P. A. Kristo, O. M. Conneely, W. G. Beattie, T. Zarucki-Schulz, B. W. O'Malley, and M. S. Kulomaa. 1987. Molecular cloning of the chicken avidin cDNA. Nucleic Acids Res. 15:3595.
21. Oi, V. T., and S. L. Morrison. 1986. Chimeric antibodies. Biotechniques 4:214.
22. Shin, S.-U., and S. L. Morrison. 1989. Production and properties of chimeric antibody molecules. Methods Enzymol. 178:459.
23. Morrison, S. L., S. Canfield, S. Porter, L. K. Tan, M. H. Tao, and L. A. Wims. 1988. Production and characterization of genetically engineered antibody molecules. Clin. Chem. 34:1668.
24. Kang, Y.-S., and W. M. Pardridge. 1994. Use of neutral-avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. J. Pharmacol. Exp. Ther. 269:344.
25. Pardridge, W. M., R. J. Boado, and Y.-S. Kang. 1995. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. USA 92:5592.
26. Friden, P. M., L. R. Walus, P. Watson, S. R. Doctrow, J. W. Kozarich, C. Backman, H. Bergman, B. Hoffer, F. Bloom, and A. C. Granholm. 1993. Blood-brain barrier penetration and in vivo activity of an NOF conjugate. Science 259:373.
27. Kordower, J. H., V. Charles, R. Bayer, R. T. Bartus, S. Putney, L. R. Walus, and P. M. Friden. 1994. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proc. Natl. Acad. Sci. USA 91:9077.
28. Bickel, U., T. Yoshikawa, E. M. Landaw, K. F. Faull, and W. M. Pardridge. 1993. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA 90:2618.
29. Pardridge, W. M., Y.-S. Kang, and J. L. Buciak. 1994. Transport of human recombinant brain derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharmacol. Res. 11:738.
30. Pugliese, L., A. Coda, M. Malcovati, and M. Bolognesi. 1993. Three-dimensional structure of the tetragonal crystal form of egg-white avidin in its functional complex with biotin at 2.7 A resolution. J. Mol. Biol. 231:698.
31. Marshall, D., R. B. Pedley, J. A. Boden, R. Boden, R. G. Melton, and R. H. Begent. 1996. Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated antitumour antibody. Br. J. Cancer 73:565.
32. Weiner, H. L. 1994. Oral tolerance. Proc. Natl. Acad. Sci. USA 91:10762.
33. 3H]biotin bound to different avidin analogues. J. Drug Target. 3:159.
34. Crone, C., and S. P. Olesen. 1982. Electrical resistance of brain microvascular endothelium. Brain Res. 241:49.
35. Hnatowich, D. J., F. Virzi, and M. Rusckowski. 1987. Investigations of avidin and biotin for imaging applications. J. Nucl. Med. 28:1294.
36. Dosio, F., P. Magnani, G. Paganelli, A. Samuel, G. Chiesa, and F. Fazio. 1993. Three-step tumor pre-targeting in lung cancer immunoscintigraphy. J. Nucl. Biol. Med. 37:228.
37. Yao, Z., M. Zhang, H. Kobayashi, H. Sakahara, H. Nakada, I. Yamashina, and J. Konishi. 1995. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J. Nucl. Med. 36:837.